We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+51.52%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$361M
AUM Growth
+$93.2M
Cap. Flow
+$8.94M
Cap. Flow %
2.48%
Top 10 Hldgs %
42.47%
Holding
67
New
20
Increased
17
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$9.16M
2
ASND icon
Ascendis Pharma A/S
ASND
+$8.32M
3
NVTA
Invitae Corporation
NVTA
+$7.76M
4
OCUL icon
Ocular Therapeutix
OCUL
+$7.64M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.14M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$24.5M
2
BPMC
Blueprint Medicines
BPMC
+$12.6M
3
AMRN
Amarin Corp
AMRN
+$10.9M
4
XNCR icon
Xencor
XNCR
+$6.51M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$5.74M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Miscellaneous 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
51
DELISTED
La Jolla Pharmaceutical Company
LJPC
$386K 0.11%
+60,000
New +$391K
BLRX
52
BioLineRX
BLRX
$12.1M
$108K 0.03%
417
– –
ASRT
53
DELISTED
Assertio
ASRT
– –
-2,000
Closed -$433K
COLL icon
54
Collegium Pharmaceutical
COLL
$820M
– –
-80,000
Closed -$1.37M
MGNX icon
55
MacroGenics
MGNX
$260M
– –
-150,000
Closed -$1.91M
PBYI icon
56
Puma Biotechnology
PBYI
$477M
– –
-100,000
Closed -$2.04M
PLX icon
57
Protalix BioTherapeutics
PLX
$210M
– –
-250,000
Closed -$777K
SGMO
58
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-500,000
Closed -$5.74M
VRDN icon
59
Viridian Therapeutics
VRDN
$2.71B
– –
-25,667
Closed -$1.17M
XNCR icon
60
Xencor
XNCR
$2.15B
– –
-180,000
Closed -$6.51M
IMGN
61
DELISTED
Immunogen Inc
IMGN
– –
-1,021,000
Closed -$4.9M
SIOX
62
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-72,500
Closed -$577K
PTE
63
DELISTED
PolarityTE, Inc. Common Stock
PTE
– –
-16,000
Closed -$5.4M
ARQL
64
DELISTED
Arqule Inc
ARQL
– –
-200,000
Closed -$358K
LOXO
65
DELISTED
Loxo Oncology, Inc
LOXO
– –
-175,000
Closed -$24.5M
CTIC
66
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-1,400,000
Closed -$1.03M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2019 Portfolio in Review

As of Q1 2019, Opaleye Management held 67 positions worth $361M, up 35% from $268M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Opaleye Management's Q1 2019 filing shows 20 new, 17 increased, 12 reduced and 14 closed positions. Its largest new stake was uniQure: 205,000 shares worth $12.2M. The largest sale was Loxo Oncology, Inc, an estimated $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q1 2019 buy was uniQure: 205,000 shares worth $12.2M.
  • Opaleye Management added most to Odonate Therapeutics, Inc. Common Stock in Q1 2019, an estimated $4.83M increase.
  • Opaleye Management's biggest Q1 2019 reduction was Blueprint Medicines, cutting an estimated $12.6M.
  • Opaleye Management fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $24.5M.
  • Opaleye Management's ten largest holdings make up 42% of its $361M portfolio in Q1 2019.
  • Opaleye Management opened 20 new positions and closed 14 in Q1 2019.
  • Opaleye Management's portfolio value rose 35% quarter-over-quarter to $361M.

Based on Opaleye Management's 13F filing for Q1 2019, filed 15 May 2019.